KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to 15136.34%.

  • CRISPR Therapeutics AG's EBITDA Margin fell 150073600.0% to 15136.34% in Q4 2025 from the same period last year, while for Dec 2025 it was 16484.84%, marking a year-over-year decrease of 155031100.0%. This contributed to the annual value of 16484.84% for FY2025, which is 155031100.0% down from last year.
  • According to the latest figures from Q4 2025, CRISPR Therapeutics AG's EBITDA Margin is 15136.34%, which was down 150073600.0% from 11866.82% recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's EBITDA Margin peaked at 84.27% during Q2 2021, and registered a low of 1732650.0% during Q4 2022.
  • For the 5-year period, CRISPR Therapeutics AG's EBITDA Margin averaged around 117090.62%, with its median value being 15448.3% (2021).
  • As far as peak fluctuations go, CRISPR Therapeutics AG's EBITDA Margin tumbled by 2000000000bps in 2022, and later soared by 2000000000bps in 2023.
  • CRISPR Therapeutics AG's EBITDA Margin (Quarter) stood at 1128.34% in 2021, then plummeted by -153457bps to 1732650.0% in 2022, then skyrocketed by 100bps to 48.73% in 2023, then tumbled by -365bps to 128.98% in 2024, then crashed by -11635bps to 15136.34% in 2025.
  • Its EBITDA Margin stands at 15136.34% for Q4 2025, versus 11866.82% for Q3 2025 and 23390.47% for Q2 2025.